ANI PharmaceuticalsANIP
About: ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Employees: 897
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
119% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 21
26% more capital invested
Capital invested by funds: $1.07B [Q4 2024] → $1.35B (+$282M) [Q1 2025]
11% more funds holding
Funds holding: 204 [Q4 2024] → 226 (+22) [Q1 2025]
0.07% more ownership
Funds ownership: 91.71% [Q4 2024] → 91.78% (+0.07%) [Q1 2025]
14% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 73
38% less call options, than puts
Call options by funds: $535K | Put options by funds: $863K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Guggenheim Vamil Divan | 37%upside $86 | Buy Reiterated | 12 May 2025 |
Truist Securities Gregory Fraser | 4%upside $65 | Hold Maintained | 21 Apr 2025 |
HC Wainwright & Co. Oren Livnat | 50%upside $94 | Buy Reiterated | 17 Mar 2025 |
Financial journalist opinion
Based on 4 articles about ANIP published over the past 30 days
